Papers In Press, published online ahead of print September 12, 2007
J. Biol. Chem, 10.1074/jbc.M703053200
Submitted on April 11, 2007
Revised on September 12, 2007
Accepted on September 12, 2007
A yeast model of the neurogenic ataxia retinitis pigmentosa (NARP) T8993G mutation in the mitochondrial ATP synthase-6 gene
Malgorzata Rak, Emmanuel Tetaud, Stephane Duvezin-Caubet, Nahia Ezkurdia, Mailis Bietenhader, Joanna Rytka, and Jean-Paul di Rago
Institut de Biochimie et Génétique Cellulaires, CNRS/Bordeaux2 University, Bordeaux cedex 33077
Corresponding Author: jp.dirago{at}ibgc.u-bordeaux2.fr
NARP (neuropathy, ataxia and retinitis pigmentosa) and MILS (maternally inherited Leighs syndrome) are mitochondrial disorders associated with point mutations of the mitochondrial DNA (mtDNA) in the gene encoding the Atp6p subunit of the ATP synthase. The most common and studied of these mutations is T8993G converting the highly conserved leucine 156 into arginine. We have introduced this mutation at the corresponding position (183) of yeast Saccharomyces cerevisiae mitochondrially encoded Atp6p. The yeast NARP mutant grew very slowly on respiratory substrates, possibly because mitochondrial ATP synthesis was only 10% of the wild type level. The mutated ATP synthase was found to be correctly assembled and present at nearly normal levels (80% of wild type). Contrary to what has been reported for human NARP cells, the reverse functioning of the ATP synthase, i.e. ATP hydrolysis in the F1 coupled to Fo-mediated proton translocation out of the mitochondrial matrix, was significantly compromised in the yeast NARP mutant. Interestingly, the oxygen consumption rate in the yeast NARP mutant was decreased by about 80% compared to the wild type, due to a selective lowering in cytochrome c oxidase (complex IV) content. This finding suggests a possible regulatory mechanism between ATP synthase activity and complex IV expression in yeast mitochondria. The availability of a yeast NARP model could ease the search for rescuing mechanisms against this mitochondrial disease.